Calidi Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Calidi Biotherapeutics, Inc. (CLDI) on August 22, 2024. The filing serves as a Regulation FD disclosure regarding a corporate presentation made available on the Company's website concerning its new wholly owned subsidiary, Redtail Biopharma, Inc.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure event rather than financial performance data.
Material Changes
The primary material event disclosed is the establishment of Redtail Biopharma, Inc. as a wholly owned subsidiary of Calidi Biotherapeutics, Inc. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
The filing references a presentation (Exhibit 99.1) regarding the new subsidiary but does not contain specific guidance, outlook, or management commentary within the text of the 8-K itself. The Company explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the details of the new subsidiary, Redtail Biopharma, Inc., by reviewing the presentation furnished as Exhibit 99.1.
- Confirm that the information in this 8-K is not incorporated by reference into other SEC filings unless specifically cited.
- Note that this filing does not contain audited financial statements or updated financial metrics.
- Check the Company's website for the full presentation referenced in Item 7.01.